Skip to main content
Log in

Utility Estimation in Chronic Obstructive Pulmonary Disease

A Preference for Change?

  • Current Opinion
  • Utility Estimation in COPD
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Economic evaluations of chronic obstructive pulmonary disease (COPD) incorporate utilities through multi-attribute utility (MAU) measures, most commonly the EQ-5D, to report health-related quality-of-life (HR-QOL) changes or differences. Questions have been raised about the sensitivity of these measures in COPD. Limitations in detecting adequate patient-level changes inHR-QOL over time in stable and exacerbation states compared with disease-specific instruments could also result in underestimation of known treatment benefits.

The purpose of this article was to present and discuss the empirical evidence on the validity of genericMAUmeasures within the COPD population. We built upon a previously conducted validation review for the period 1997–2007 that used ‘respiratory disease’ and ‘EQ-5D’ as keywords. For this discussion, PubMed and EMBASE databases were searched for articles in English from 1988 to August 2009, using similar search words.

Based on the performance ofMAUmeasures in COPD and exacerbations, they appear to have limited discriminatory ability, particularly between moderate and severe COPD, despite known differences in HR-QOL. Sensitivity to clinically relevant change in stable COPD over time due to treatment also appears limited. Current research suggests adequate sensitivity regarding detecting the onset and resolution of an exacerbation; however, sensitivity is limited in the short term, such as daily changes in health status. The evidence suggests responsiveness of MAU measures may be restricted to large withinpatient change, which leads to difficulties in evaluating the subtle but important impact of exacerbations. Studies presenting alternative methods of deriving COPD-related utilities are also discussed.

Overall, the insensitivities of generic MAU measures in COPD can lead to biased cost-effectiveness analyses and ill-informed economic decisions. Alternative measures such as condition-specific preference-based measures may be used in circumstances where more sensitivity is needed. The trade-off allows relevant and sensitive matters most important to patients to be evaluated; however inevitable gaps such as those related to adverse events are not considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1

Similar content being viewed by others

References

  1. WHO. Chronic obstructive pulmonary disease (COPD). Fact sheet No. 315, February 2011 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs315/en/index.html [Accessed 2011 Jul 4]

    Google Scholar 

  2. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006 Sep; 28 (3): 523–32

    Article  PubMed  CAS  Google Scholar 

  3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun; 23 (6): 932–46

    Article  PubMed  CAS  Google Scholar 

  4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. GOLD, 2009 [online]. Available from URL: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003 [Accessed 2010 Sep 13]

  5. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117 (5 Suppl. 2): 398–401S

    Article  Google Scholar 

  6. Rodríguez-Roisin R. COPD exacerbations. 5: management. Thorax 2006 Jun; 61 (6): 535–44

    Article  PubMed  Google Scholar 

  7. Jones PW. Health status: what does it mean for payers and patients? Proc Am Thorac Soc 2006 May; 3 (3): 222–6

    Article  PubMed  Google Scholar 

  8. Miravitlles M, Anzueto A, Legnani D, et al. Patient’s perception of exacerbations of COPD: the PERCEIVE study. Respir Med 2007 Mar; 101 (3): 453–60

    Article  PubMed  Google Scholar 

  9. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 Oct 9; 276 (14): 1172–7

    CAS  Google Scholar 

  10. Prieto L, Sacristan JA. What is the value of social values? The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol 2004 Apr 29; 4: 10

    Google Scholar 

  11. Feeny D. Commentary on Jack Dowie, “Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions”. Health Econ 2002 Jan; 11 (1): 13–6; discussion 21-2

    Article  PubMed  Google Scholar 

  12. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 Jul; 33 (5): 337–43

    Article  PubMed  CAS  Google Scholar 

  13. Ringbaek T, Brondum E, Martinez G, et al. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008 Nov; 102 (11): 1563–7

    Article  PubMed  Google Scholar 

  14. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med 1991 Sep; 85 Suppl. B: 25–31; discussion 3-7

    Article  Google Scholar 

  15. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145 (6): 1321–7

    Google Scholar 

  16. Hesselink AE, van der Windt DA, Penninx BW, et al. What predicts change in pulmonary function and quality of life in asthma or COPD? J Asthma 2006 Sep; 43 (7): 513–9

    Article  PubMed  CAS  Google Scholar 

  17. Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. Eur Respir J 2009 May; 33 (5): 953–5

    Article  PubMed  CAS  Google Scholar 

  18. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997 Apr; 155 (4): 1283–9

    PubMed  CAS  Google Scholar 

  19. Verhage TL, Heijdra YF, Molema J, et al. Adequate patient characterization in COPD: reasons to go beyond GOLD classification. Open Respir Med J 2009; 3: 1–9

    Article  PubMed  Google Scholar 

  20. Wijnhoven HA, Kriegsman DM, Hesselink AE, et al. Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life. Chest 2001 Apr; 119 (4): 1034–42

    Article  PubMed  CAS  Google Scholar 

  21. Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ 2010 Feb; 19 (2): 125–9

    Article  PubMed  Google Scholar 

  22. Pickard AS, Wilke C, Jung E, et al. Use of a preferencebased measure of health (EQ-5D) in COPD and asthma. Respir Med 2008 Apr; 102 (4): 519–36

    Article  PubMed  Google Scholar 

  23. Brown G, Austin J, McGowan I, et al. Is the EuroQol generic health status questionnaire sensitive to the impact of pulmonary rehabilitation in COPD? [abstract]. Am J Respir Crit Care Med 2009; 179: A3852

    Google Scholar 

  24. Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997 Oct; 52 (10): 879–87

    Article  PubMed  CAS  Google Scholar 

  25. Hazell M, Frank T, Frank P. Health related quality of life in individuals with asthma related symptoms. Respir Med 2003 Nov; 97 (11): 1211–8

    Article  PubMed  Google Scholar 

  26. Punekar YS, Rodriguez-Roisin R, Sculpher M, et al. Implications of chronic obstructive pulmonary disease (COPD) on patients’ health status: a western view. Respir Med 2007 Mar; 101 (3): 661–9

    Article  PubMed  Google Scholar 

  27. Rutten-van MÖlken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8 (2): 123–35

    Article  PubMed  Google Scholar 

  28. Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56

    Article  PubMed  Google Scholar 

  29. Ståhl E, Lindberg A, Rönmark E, et al. The level of healthrelated quality of life in patients with COPD and its dependence on age, gender and disease severity. Eur Respir J 2001; 18 Suppl. 33: S184

    Google Scholar 

  30. Stavem K. Association of willingness to pay with severity of chronic obstructive pulmonary disease, health status and other preference measures. Int J Tuberc Lung Dis 2002 Jun; 6 (6): 542–9

    PubMed  CAS  Google Scholar 

  31. Stavem K.Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8 (1-2): 45–54

    Article  PubMed  CAS  Google Scholar 

  32. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Medical Care 2005; 43 (7): 736–49

    Article  PubMed  Google Scholar 

  33. Szende A, Leidy NK, Stahl E, et al. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res 2009 Mar; 18 (2): 267–72

    Article  PubMed  CAS  Google Scholar 

  34. Goossens L, Rutten-van Mölken M, Nivens C. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? ISPOR 11th Annual European Congress; 2008 Nov 8–11; Athens

    Google Scholar 

  35. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations: comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010; 8 (1): 39

    Article  PubMed  Google Scholar 

  36. O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007 Jul; 61 (7): 1112–20

    Article  PubMed  Google Scholar 

  37. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the Measure Your Medical Outcome Profile (MYMOP), Medical Outcomes Study 6-Item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000; 9 (5): 521–7

    Article  PubMed  CAS  Google Scholar 

  38. Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999; 16 (5 Pt 1): 499–520

    Article  PubMed  CAS  Google Scholar 

  39. Vardeva K, Spencer MD, Punekar Y. Development of preference-based EQ-5D utility values for the St George’s Respiratory Questionnaire: Chronic Obstructive Pulmonary Disease (SGRQ-COPD). 10th Annual ISPOR European Congress; 2007 Oct 20–23; Dublin

    Google Scholar 

  40. Starkie H, Briggs A, Chambers M. Mapping the St George’s Respiratory Questionnaire to utility values using the EQ5D. 30th Annual Meeting of the Society for Medical Decision Making; 2008 Oct 19–22; Philadelphia (PA)

    Google Scholar 

  41. Marra CA, Sullivan SD, Najafzadeh M, et al. Mapping the EQ-5D from the St. George’s Respiratory Questionnaire in a clinical trial of COPD treatments: results from the OPTIMAL trial. 10th Annual ISPOR European Congress; 2007 Oct 20–23; Dublin

    Google Scholar 

  42. Meguro M, Jones PW. Item selection for COPD-specific utility instrument (abstract no. PCO2). Value Health 2004; 7 (6): 684

    Article  Google Scholar 

  43. Meguro M, Jones PW. Elicitation of utility weights for a COPD specific preference measure [abstract]. Am J Resp Crit Care Med 2006; 3: A488

    Google Scholar 

  44. Petrillo J, Cairns J. Development of the EXACT-U: a preference-based measure to report COPD exacerbation utilities. Value Health 2011; 14 (4): 546–54

    Article  PubMed  Google Scholar 

  45. Rutten-van MÖlken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009; 27 (6): 465–77

    Article  PubMed  Google Scholar 

  46. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004 Sep; 13 (9): 873–84

    Article  PubMed  Google Scholar 

  47. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35 (11): 1095–108

    Article  PubMed  CAS  Google Scholar 

  48. Feeny D, Furlong W, Boyle M, et al. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490–502

    Article  PubMed  CAS  Google Scholar 

  49. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988 Jun; 23 (2): 203–35

    PubMed  CAS  Google Scholar 

  50. Kaplan RM, Ganiats TG, Sieber WJ, et al. The Quality of Well-Being scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998 Dec; 10 (6): 509–20

    Article  PubMed  CAS  Google Scholar 

  51. Rutten-van MÖlken M, Roos B, Van Noord JA. An empirical comparison of the St. George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999 Nov; 54 (11): 995–1003

    Google Scholar 

  52. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 503–20

    Article  PubMed  CAS  Google Scholar 

  53. National Institute for Health and Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: NICE, 2008

    Google Scholar 

  54. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008 Feb; 31 (2): 416–69

    Article  PubMed  CAS  Google Scholar 

  55. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004 Mar-Apr; 7 (2): 153–67

    Article  PubMed  Google Scholar 

  56. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619–37

    Article  PubMed  CAS  Google Scholar 

  57. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006 Oct; 130 (4): 1117–28

    Article  PubMed  Google Scholar 

  58. Rutten-van Mölken MRV, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (7): 630–4

    Article  PubMed  Google Scholar 

  59. McBride A, Milne R. Hospital-based pulmonary rehabilitation programmes for patients with severe chronic obstructive pulmonary disease. Southampton: Wessex Institute for Health Research and Development, University of Southampton, 1999. DEC report No. 94

    Google Scholar 

  60. Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 Mar 1; 171 (5): 446–52

    Article  PubMed  Google Scholar 

  61. Brooks R. The measurement and valuation of health status using EQ-5D: a European perspective. In: Brooks R, Rabin R, de Charro F, editors. Evidence from the Euro-Qol BIO MED Research Programme. Dordrecht: Kluwer Academic Publishers, 2003

    Google Scholar 

  62. Bharmal M, Thomas J. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006; 9 (4): 262–71

    Article  PubMed  Google Scholar 

  63. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003 Jun; 41: 29–35s

    Article  Google Scholar 

  64. Buss AS, da Silva LM. Comparative study of two quality of life questionnaires in patients with COPD. J Bras Pneumol 2009 Apr; 35 (4): 318–24

    Article  PubMed  Google Scholar 

  65. Briggs A, Glick H, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010; 35 (3): 532–9

    Article  PubMed  CAS  Google Scholar 

  66. Decramer M, Dekhuijzen PN, Troosters T, et al. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS trial Committee. Eur Respir J 2001 Mar; 17 (3): 329–36

    CAS  Google Scholar 

  67. Guyatt GH, King DR, Feeny DH, et al. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999 Mar; 52 (3): 187–92

    Article  PubMed  CAS  Google Scholar 

  68. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD: a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009; 4 (1): 203–23

    Article  PubMed  Google Scholar 

  69. Bourbeau J, Ford G, Zackon H, et al. Impact on patients’ health status following early identification of a COPD exacerbation. Eur Respir J 2007 Nov; 30 (5): 907–13

    Article  PubMed  CAS  Google Scholar 

  70. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002 Mar; 121 (3): 688–96

    Article  PubMed  Google Scholar 

  71. Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 2008; 28 (1): 66–89

    Google Scholar 

  72. Petrillo J, Cairns J. Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Exp Rev Pharmacoeconomics Outcomes Res 2008; 8 (5): 453–61

    Article  Google Scholar 

  73. Brazier J, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition-specific measure: the King’s health questionnaire. Med Decis Making 2008; 28 (1): 113–26

    Article  PubMed  Google Scholar 

  74. McKenna SP, Ratcliffe J, Meads DM, et al. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008; 6: 65

    Article  PubMed  Google Scholar 

  75. Koltowska-Haggstrom M, Jonsson B, Isacson D, et al. Using EQ-5D to derive general population-based utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA). Value Health 2007; 10 (1): 73–81

    Article  PubMed  Google Scholar 

  76. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest 1998; 114 (4): 998–1007

    Article  PubMed  CAS  Google Scholar 

  77. Brazier J, Dixon S. The use of condition specific outcome measures in economic appraisal. Health Econ 1995; 4 (4): 255–64

    Article  PubMed  CAS  Google Scholar 

  78. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD. Version 1.2. New York: American Thoracic Society, 2004 [online]. Available from URL: http://www.thoracic.org/go/copd [Accessed 2005 Sep 8]

    Google Scholar 

  79. Fan VS, Ramsey SD, Make BJ, et al. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD 2007 Mar; 4 (1): 29–39

    Article  PubMed  Google Scholar 

  80. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010; 13 (8): 965–75

    Article  PubMed  Google Scholar 

  81. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183 (3): 323–9

    Article  PubMed  Google Scholar 

  82. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42 (9): 851–9

    Article  PubMed  Google Scholar 

  83. McTaggart-Cowan HM, Marra CA, Yang Y, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Quality Life Res 2008; 17 (3): 453–62

    Article  Google Scholar 

  84. Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006; 24 (11): 1069–78

    Article  PubMed  Google Scholar 

  85. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008 Nov; 63 (11): 962–7

    Article  PubMed  CAS  Google Scholar 

  86. Petrillo J, Macker S, Davies E, et al. Development of a preference-based algorithm to report utilities for exacerbations of COPD from the EXACT. Value Health 2011; (14) 546–54

    Article  PubMed  Google Scholar 

  87. Petrillo J, Cairns J. Evaluation of COPD exacerbations using the EXACT-U. European Respiratory Society Annual Congress; 2010 Sep 18–22; Barcelona

    Google Scholar 

  88. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3 (9): iii-163

    Google Scholar 

  89. Mahler DA, Mackowiak JI. Evaluation of the shortform 36-Item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995 Jun; 107 (6): 1585–9

    Article  PubMed  CAS  Google Scholar 

  90. Burstrom K, Johannesson M, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006; 76 (3): 359–70

    Article  PubMed  Google Scholar 

  91. Stiggelbout AM, de Vogel-Voogt E. Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 2008 Jan-Feb; 11 (1): 76–87

    Article  PubMed  Google Scholar 

  92. US FDA. Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Rockville (MD): US Department of Health and Human Services, 2007 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071575.pdf [Accessed 2010 Sep 21]

    Google Scholar 

  93. US FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville (MD): US Department of Health and Human Services, 2009 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf [Accessed 2010 Sep 21]

    Google Scholar 

  94. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009; 7: 27

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The development of this article was supported by funds from Nycomed to United BioSource Corporation (UBC). Jennifer Petrillo was, and Floortje van Nooten is, employed by UBC, which provides consulting and other research services to pharmaceutical, device, government and non-government organizations. In this salaried position, they work with a variety of companies and organizations. They receive no payment or honoraria directly from these organizations for services rendered.

Maureen Rutten-van Mölken has received funding from Nycomed to assess the cost effectiveness of one of their products, i.e. roflumilast. She has also received a consultancy fee to advise on the cost-effectiveness model of roflumilast. Paul Jones has received £1500 for participating in a mock US FDA Advisory Board.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer Petrillo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrillo, J., van Nooten, F., Jones, P. et al. Utility Estimation in Chronic Obstructive Pulmonary Disease. Pharmacoeconomics 29, 917–932 (2011). https://doi.org/10.2165/11589280-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589280-000000000-00000

Keywords

Navigation